Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 1 Nov 2012

Park Soo Yong, Rim Min Young, Yo In Ku, Ha Min Su, Kim Ju Seung, Lee Ji Won, Jung Young Kul, Kwon Oh Sang, Kim Yun Soo, Choi Duck Joo, Kim Ju Hyun

Abstract excerpt

BACKGROUND/AIMS: A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. METHODS: Twenty-eight...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 23172279
DOI: 10.4166/kjg.2012.60.5.306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].PMID 23172279Read ↗

[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].Semantic proximity Read ↗

[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].Semantic proximity Read ↗

[Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].Semantic proximity Read ↗

[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].Semantic proximity Read ↗

[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].Semantic proximity Read ↗

Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.Semantic proximity Read ↗

[Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].Semantic proximity Read ↗

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study.Semantic proximity Read ↗

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.Semantic proximity Read ↗

[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].Semantic proximity Read ↗

[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.